PT - JOURNAL ARTICLE AU - Park, Julien AU - Bremova-Ertl, Tatiana AU - Brands, Marion AU - Foltan, Tomas AU - Gautschi, Matthias AU - Gissen, Paul AU - Hahn, Andreas AU - Jones, Simon AU - Arash-Kaps, Laila AU - Kolnikova, Miriam AU - Patterson, Marc AU - Perlman, Susan AU - Ramaswami, Uma AU - Reichmannová, Stella AU - Rohrbach, Marianne AU - Schneider, Susanne AU - Shaikh, Aasef AU - Sivananthan, Siyamini AU - Synofzik, Matthis AU - Walterfarng, Mark AU - Wibawa, Pierre AU - Martakis, Kyriakos AU - Manto, Mario TI - Assessment of the Reliability, Responsiveness, and Meaningfulness of the Scale for the Assessment and Rating of Ataxia (SARA) for Lysosomal Storage Disorders AID - 10.1101/2024.07.19.24310680 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.19.24310680 4099 - http://medrxiv.org/content/early/2024/07/19/2024.07.19.24310680.short 4100 - http://medrxiv.org/content/early/2024/07/19/2024.07.19.24310680.full AB - Objective To evaluate the reliability, responsiveness, and validity of the Scale for the Assessment and Rating of Ataxia (SARA) in patients with Lysosomal Storage Disorders (LSDs) who present with neurological symptoms and quantify the threshold for a clinically meaningful change.Methods We analyzed data from three clinical trial cohorts (IB1001-201, IB1001-202, IB1001-301) of patients with Niemann-Pick disease type C (NPC) and GM2 Gangliosidoses (Tay-Sachs and Sandhoff disease) comprising 122 patients and 703 visits. Reproducibility was described as retest reliability between repeat baseline visits or baseline vs. post-treatment washout visits. Responsiveness was determined in relation to the Investigator’s, Caregiver’s, and Patient’s Clinical Global Impression of Improvement (CGI-I). The CGI-I data was also used to quantify a threshold for a clinically meaningful improvement on the SARA scale. Using a qualitative methods approach, patient/caregiver interviews from the IB1001-301 trial were further used to assess a threshold of meaningful change as well as the breadth of neurological signs and symptoms captured and evaluated by the SARA scale.Results The Inter-Class Correlation (ICC) was 0.95 or greater for all three trials, indicating a high internal consistency/reliability. The mean change in SARA between repeat baseline or post-treatment washout visit assessments in all trials was -0.05, SD 1.98, i.e. minimal, indicating no significant differences, learning effects or other systematic biases. For the CGI-I responses and change in SARA scores Area Under the Curve (AUC) values were 0.82, 0.71, and 0.77 for the Investigator’s, Caregiver’s, and Patient’s CGI-I respectively, indicating strong agreement. Further qualitative analyses of the patient/caregiver interviews demonstrated a 1-point or greater change on SARA to be a clinically meaningful improvement which is directly relevant to the patient’s everyday functioning and quality of life. Changes captured by the SARA were also paralleled by improvement in a broad range of neurological signs and symptoms and beyond cerebellar ataxia.Conclusion Qualitative and quantitative data demonstrate the reliability and responsiveness of the SARA score as a valid measure of neurological signs and symptoms in LSDs. A 1-point change represents a clinically meaningful transition reflecting the gain or loss of complex function.Statements and Declarations The IB1001-201, IB1001-202, and IB1001-301 trials were funded by IntraBio Inc. No funding was received to assist with the preparation of this manuscript.T. Bremova-Ertl received honoraria for lecturing from Sanofi and Acetlion and fees from IntraBio to serve as a blinded rater for the IB1001-201 and IB1001-202 clinical trials. P. Gissen received consulting fees from Mandos Health and is the Co-Founder and shareholder of Bloomsbury Genetic Therapies. M. Patterson is a shareholder in IntraBio and his institution has received research grants from Azafaros, Glycomine, Idorsia, Maggie’s Pearl, Takeda, and Zevra, and consulting fees (directed to his institution) from Zevra. U. Ramaswami has received research and/or investigator-initiated research grants from Amicus and Takeda and honoraria for advisory boards and lectures from Amicus, Takeda, and Sanofi. All other authors The authors have no competing interests to declare that are relevant to the content of this article.Competing Interest StatementT. Bremova-Ertl received honoraria for lecturing from Sanofi and Acetlion and fees from IntraBio to serve as a blinded rater for the IB1001-201 and IB1001-202 clinical trials. P. Gissen received consulting fees from Mandos Health and is the Co-Founder and shareholder of Bloomsbury Genetic Therapies. M. Patterson is a shareholder in IntraBio and his institution has received research grants from Azafaros, Glycomine, Idorsia, Maggies Pearl, Takeda, and Zevra, and consulting fees (directed to his institution) from Zevra. U. Ramaswami has received research and/or investigator-initiated research grants from Amicus and Takeda and honoraria for advisory boards and lectures from Amicus, Takeda, and Sanofi. All other authors The authors have no competing interests to declare that are relevant to the content of this article.Clinical Protocols https://www.nejm.org/doi/full/10.1056/NEJMoa2310151 https://clinicaltrials.gov/study/NCT03759639?cond=Niemann-Pick%20Disease%20Type%20C&rank=8&tab=results Funding StatementThe IB1001-201, IB1001-202, and IB1001-301 trials were funded by IntraBio Inc. No funding was received to assist with the preparation of this manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of Ludwig Maximilian University of Munich, Slovakia: National Institute of Child Diseases Bratislava Ethics Committee, Bellvitge Hospital University Clinical Research Ethics Committee, East Midlands Derby Research Ethics Committee, Mayo Clinic Institutional Review Board, North West Greater Manchester South, New York University School of Medicine, University of California Los Angeles Institutional Review Board, Victoria Human Research Ethics Committee, Ethics Committee of General University Hospital in Prague, Amsterdam UMC Locatie AMC, Kantonale Ethikkommission Bern (KEK) gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. The study documents related to the study, and datasets generated and analyzed during the current study are not publicly available. No individual, de-identified participant data will be shared.